PE-22-28 Protocol Guide
PE-22-28 (also written PE22-28) is a synthetic peptide analogue of BDNF (Brain-Derived Neurotrophic Factor) that acts as a TrkB receptor agonist. It is researched for depression, anxiety, and neuroplasticity — promoting neurogenesis and serotonergic neurotransmission via the TrkB signaling pathway. PE-22-28 is a CNS/nootropic compound and is not related to hair loss or cosmetic applications. This protocol covers intranasal and subcutaneous dosing, reconstitution from a 5mg vial, and stacking recommendations for depression and cognitive enhancement research.
Protocol Overview
- Compound
- PE-22-28 (PE22-28; BDNF TrkB receptor agonist analogue)
- Category
- Nootropic / Antidepressant Research Peptide
- Mechanism
- TrkB (BDNF receptor) agonist; promotes neuroplasticity, neurogenesis, and serotonergic neurotransmission. Researched for depression, anxiety, and cognitive enhancement.
- Vial Size
- 5mg lyophilized powder (typical)
- Route
- Intranasal OR subcutaneous injection
- Frequency
- 1–2x daily
- Cycle Length
- 4–8 weeks
Dosing Protocol
| Protocol | Dose | Frequency | Route | Duration |
|---|---|---|---|---|
| Intranasal Standard | 500 mcg–1 mg per nostril (1–2 mg total) | 1–2x daily | Intranasal | 4–8 weeks |
| SubQ Conservative Start | 250 mcg | 1x daily (AM) | Subcutaneous | 1–2 weeks, then reassess |
| SubQ Standard | 500 mcg | 1x daily (AM) | Subcutaneous | 4–8 weeks |
Key principle: PE-22-28 mimics BDNF and is researched for depression, anxiety, and neuroplasticity. It is a CNS/nootropic compound — NOT a hair loss peptide. Intranasal delivery is the most common route for CNS targeting. Start at the lower end of the dosing range.
Reconstitution Instructions
Materials Needed
- PE-22-28 5mg lyophilized vial
- Bacteriostatic water (2mL)
- 3mL mixing syringe (18-20ga)
- Insulin syringes (29-31ga) for SubQ dosing
- Nasal atomizer device for intranasal dosing
- Alcohol swabs
Reconstitution Steps
- Clean vial stopper with alcohol
- Draw 2mL bacteriostatic water into mixing syringe
- Inject slowly down the vial wall to avoid foaming
- Gently swirl (never shake)
- Wait 5 minutes for full dissolution
- Concentration: 2,500 mcg/mL
| Dose | Volume (2mL recon at 2,500 mcg/mL) | Insulin Syringe / Nasal Device |
|---|---|---|
| 250 mcg (SubQ conservative) | 0.10 mL | 10 units SubQ |
| 500 mcg (SubQ standard / intranasal 1 nostril) | 0.20 mL | 20 units SubQ or 0.2 mL nasal atomizer |
| 1 mg (intranasal, 500 mcg each nostril) | 0.40 mL total | 0.2 mL per nostril via atomizer |
| 2 mg (intranasal 2x daily, 1 mg per dose) | 0.40 mL per dose | 0.2 mL per nostril, twice daily |
Administration Guide
Injection Sites
- Abdomen: Primary site, subcutaneous
- Thigh: Outer thigh, alternate sides
- Upper arm: Back of arm, alternate
Timing & Storage
- Timing: Morning administration for cognitive effects during the day
- Vial duration: ~200 days at 50mcg/day
- Storage (reconstituted): Refrigerate 2-8°C, use within 30 days
- Do not freeze reconstituted solution
Expected Timeline
Side Effects & Monitoring
Common Side Effects
- Injection site irritation (mild)
- Vivid dreams (commonly reported)
- Mild headache during initial days
- Increased mental stimulation/difficulty sleeping if dosed late
Limited safety data exists. PE-22-28 is a research compound with no human clinical trials completed. Exercise caution with dosing.
Precautions
- No human clinical trial data - preclinical only
- HGF/c-Met activation may theoretically promote tumor growth in predisposed individuals
- Avoid if history of cancer
- Extreme potency requires precise dosing - errors carry higher risk
- Not recommended during pregnancy or breastfeeding
Stacking Recommendations
Compatible Compounds
- Semax: Complementary nootropic via BDNF/NGF pathway
- Selank: Anxiolytic support; reduces anxiety alongside mood improvement
- Dihexa: HGF/c-Met agonist synergy for cognition and neuroplasticity
- BPC-157: Systemic repair and gut-brain axis support
- NAD+: Cellular energy for neuronal metabolism
Popular Stacks
- Depression/Mood: PE-22-28 500 mcg intranasal + Selank 300 mcg intranasal
- Cognitive: PE-22-28 + Semax 600 mcg/day + NAD+
- Neuroplasticity: PE-22-28 + Dihexa + BPC-157
Blood Work Recommendations
| Panel | Markers | Timing |
|---|---|---|
| Basic Panel | CBC, CMP | Baseline, Week 4 |
| Liver Function | ALT, AST, GGT | Baseline, Week 4 |
| Kidney | BUN, creatinine, eGFR | Baseline, Week 4 |
| Inflammatory | CRP, homocysteine | Baseline |
Monitoring is primarily precautionary given the limited human safety data. Track liver and kidney markers to ensure no organ stress from the compound.
Related Tools & Resources
